David Campbell compensation by year
Janux Therapeutics Summary Compensation Table · all 6 fiscal years held| Component | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Salary | $405,117 | $459,054 | $550,000 | $625,000 | $646,000 | $680,000 |
| Bonus | $141,791 | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $0 | $0 | $0 | $0 | $4,981,500 | $0 |
| Option awards | $225,868 | $7,721,848 | $5,149,378 | $3,155,769 | $2,862,873 | $12,459,031 |
| Non-equity incentive | $0 | $229,527 | $302,500 | $412,500 | $484,500 | $367,200 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $38,906 | $0 | $0 | $0 | $0 | $0 |
| Total | $811,682 | $8,410,429 | $6,001,878 | $4,193,269 | $8,974,873 | $13,506,231 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Janux Therapeutics, Inc. DEF 14A filed April 28, 2026, accession 0001193125-26-187095, and prior-year filings.
How this page was built: the Janux Therapeutics, Inc. filed document, accession 0001193125-26-187095. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 81,000 | $1,117,800 | — |
| Option | 83,959 | — | $14.02 |
| Option | 7,381 | — | $20.24 |
| Option | 185,678 | — | $11.02 |
| Option | 283,500 | — | $53.24 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Janux Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
3 Form 4 lines since the FY2025 proxy (filed April 28, 2026)current to 2026-11-07 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-07-31 | Gift | — | 123,840 | $0.00 | 264,742 |
| 2026-07-08 | Exercise or conversion derivative | — | 7,000 | $0.00 | 697,550 |
| 2026-07-08 | Exercise or conversion | — | 7,000 | $4.21 | 388,582 |
The 3 most recent of 3 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Janux Therapeutics’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| David Campbell · this page | President and Chief Executive Officer | $13,506,231 |
| Byron Robinson | Former Chief Strategy Officer | $5,063,635 |
| Janeen Doyle | Chief Corporate and Business Development Officer | $4,669,292 |
| Zachariah McIver | Former Chief Medical Officer | $4,639,495 |
| Thomas DiRaimondo | Chief Scientific Officer | $4,345,469 |
Board service
Janux Therapeutics board · FY2024–FY2025How this board is paid
Company policy: Janux Therapeutics pays directors a $45,000 cash retainer and $326,716 in equity. As stated in Janux Therapeutics's FY2025 proxy.
The full Janux Therapeutics compensation record
free company briefThis page is one person within Janux Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Janux Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Janux Therapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Janux Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.